A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Completed · Phase 2 · NCT04244175

Conditions: Seizures

Research payments reported, 2025: $278,347
U.S. investigators named: 33
Sites paid: 38
Planned or actual enrollment: 154

About the trial

Sponsor: AbbVie
Tested: Placebo (drug), CVL-865 (drug)
Dates: Started 2020-01-27; completion 2024-05-21
Results posted: Yes

The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures. It will also learn about the safety of CVL-865. The main question it aims to answer is whether CVL-865, when taken regularly with other anti-seizure medicines, lowers the number of seizures in those with a diagnosis of epilepsy with drug-resistant focal onset seizures. This study has an 8-week Screening/Baseline Period, a 13-week Treatment Period (including a 2-week Titration Phase, an 8-week Maintenance Phase, and a 3-week Taper Phase), and a 4-week Safety Follow-Up Period. Participants will take CVL-…

From ClinicalTrials.gov, last updated 2025-05-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $278,347 in research payments for this study in 2025 (67 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it